An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Lupartumab amadotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 19 Jul 2019 Status changed from discontinued to completed.
- 21 Dec 2018 Status changed from completed to discontinued.
- 19 Sep 2018 Status changed from active, no longer recruiting to completed.